Lisa Wolffe
Nurse Practitioner · Jeffersonville, OHNPI 1790345981
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 612 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,272, 2.2 times the $1,492 reported in 2021. Among nurse practitioner clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 612 payments — averaging $17.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- Vanda Pharmaceuticals Inc.$821
- Neurocrine Biosciences, Inc.$673
- plus $3K from 13 others
What the payments were for
- Food & beverage$10,21897%
- Education$3583%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 94 | $1,628 |
| AbbVie | 112 | $1,499 |
| Otsuka America Pharmaceutical, Inc. | 92 | $1,489 |
| Alkermes, Inc. | 66 | $1,095 |
| Vanda Pharmaceuticals Inc. | 35 | $821 |
| Neurocrine Biosciences, Inc. | 36 | $673 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $569 |
| E.r. Squibb & Sons, L.L.C. | 22 | $499 |
| Indivior Inc. | 29 | $445 |
| Lundbeck LLC | 26 | $432 |
| Axsome Therapeutics, Inc. | 14 | $420 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $289 |
| Supernus Pharmaceuticals, Inc. | 12 | $221 |
| Sunovion Pharmaceuticals Inc. | 10 | $211 |
| Ironshore Pharmaceuticals Inc. | 8 | $147 |
| Johnson & Johnson | 4 | $73 |
| Idorsia Pharmaceuticals US Inc | 2 | $38 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Luye Pharma (USA) Ltd. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COBENFY$215
How this compares
$10,576 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 83 | $292,687 |
| Austedo XrDeutetrabenazine | 19 | $164,279 |
| RexultiBrexpiprazole | 80 | $116,667 |
| Abilify MaintenaAripiprazole | 36 | $105,286 |
| VraylarCariprazine Hcl | 53 | $81,730 |
| PerserisRisperidone | 25 | $74,844 |
| TrintellixVortioxetine Hydrobromide | 88 | $45,398 |
| Lurasidone Hcl | 67 | $19,089 |
| Aripiprazole | 91 | $10,412 |
| Paliperidone ErPaliperidone | 39 | $7,638 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 65 | $3,234 |
| Hydroxyzine Hcl | 126 | $2,856 |
| Quetiapine Fumarate | 188 | $2,767 |
| Duloxetine Hcl | 177 | $2,491 |
| Carbamazepine ErCarbamazepine | 39 | $1,517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $73 | $292,68783 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,489 | $221,953116 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,628 | $164,27919 claims |
| AbbVieVraylar | $1,499 | $81,73053 claims |
| Indivior Inc.Perseris | $445 | $74,84425 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $289 | $45,39888 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Other nurse practitioner in Jeffersonville
- Margaret BobonichCleveland$235K
- Mary GallagherWestlake$229K
- Sonia HissettCincinnati$179K
- Ashley TaylorNew Albany$107K
- Beth FaimanCleveland$101K
- Katherine AlexanderColumbus$99K
- Tiffany JonesCincinnati$99K
- Kate NewmanWestlake$78K
- Daniella GerySouth Euclid$73K
- Amy HazelCanton$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.